ADAPTIVE BIOTECHNOLOGIES CORPORATION - COMMON STOC

Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline

07 ноя 2023 06:30:36 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023

02 ноя 2023 15:05:00 Источник Nasdaq GlobeNewswire

Adaptive Announces Launch of Epic Integration for clonoSEQ®

13 сен 2023 06:30:49 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

30 авг 2023 15:30:00 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results

02 авг 2023 15:05:54 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Second Quarter Financial Results on August 2, 2023

10 июл 2023 15:05:00 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer

02 июн 2023 06:34:30 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences

24 май 2023 15:05:00 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

12 май 2023 07:00:00 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology

09 май 2023 06:30:35 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports First Quarter 2023 Financial Results

03 май 2023 15:05:01 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the BofA Securities 2023 Healthcare Conference

25 апр 2023 15:05:00 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline

12 апр 2023 06:30:43 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023

06 апр 2023 15:05:00 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the 43rd Annual Cowen Healthcare Conference

27 фев 2023 15:05:00 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results

14 фев 2023 15:05:01 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023

23 янв 2023 15:05:00 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference

27 дек 2022 15:05:00 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting

10 дек 2022 09:00:00 Источник Nasdaq GlobeNewswire

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting

05 дек 2022 06:30:00 Источник Nasdaq GlobeNewswire